Biotech

All Articles

Cullinan, after $25M package, hands back bispecific to Harbour

.Cullinan Therapy was excited enough along with Harbour BioMed's bispecific invulnerable reactor tha...

A closer examine Fierce Biotech's Tough 15

.In this particular week's incident of "The Best Line," we're diving in to Tough Biotech's yearly Fe...

Lilly experiences period 2 failure of tau-targeting med

.The confetti is actually still soaring coming from Eli Lilly's gathering celebrating the approval o...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our summary of considerable leadership hirings, firings...

Lykos are going to ask FDA to reexamine its selection observing being rejected of MDMA treatment for post-traumatic stress disorder

.Complying with an inadequate revealing for Lykos Rehabs' MDMA applicant for trauma at a recent FDA ...

AN 2 halves head count, quits period 3 trial after records let down

.AN2 Therapies is re-thinking its organization in response to poor midphase records, vowing to lay o...

Merck pays $700M for bispecific, snooping autoimmune opening and opportunity to test Amgen in cancer cells

.Merck &amp Co. is actually spending $700 thousand upfront to challenge Amgen in a blood cancer cell...

Gilead pays out J&ampJ $320M to go out licensing offer for seladelpar

.Along With Gilead Sciences on the verge of an FDA selection for its own liver condition medication ...

' All hands on deck' at Lilly as peers target weight problems market

.CEO David Ricks may find the companies establishing camping tents at basecamp behind Eli Lilly in a...

Entero laying off staff, moving out of office and also pausing R&ampD

.Cushion Liquidators has transformed Entero Therapeutics white as a piece. The lender got Entero to ...